A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
Amy S Chappell1, Laurence A Bradley2, Curtis Wiltse1, Michael J Detke1,3,4, Deborah N D’Souza1, Michael Spaeth5
1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of Alabama at Birmingham, Birmingham, Alabama, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Harvard Medical School, Boston, MA, USA; 5Practice for Internal Medicine/Rheumatology, Graefelfing, Germany
Objective: Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment.
Methods: This was a phase-III, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of duloxetine.
Results: There were no significant differences between treatment groups on the co-primary efficacy outcome measures, change in the Brief Pain Inventory (BPI) average pain severity from baseline to endpoint (P = 0.053) and the Patient’s Global Impressions of Improvement (PGI-I) at endpoint (P = 0.073). Duloxetine-treated patients improved significantly more than placebo-treated patients on the Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score. Nausea was the most common treatment-emergent adverse event in the duloxetine group. Overall discontinuation rates were similar between groups.
Conclusions: Although duloxetine 60/120 mg/day failed to demonstrate significant improvement over placebo on the co-primary outcome measures, in this supportive study, duloxetine demonstrated significant improvement compared with placebo on numerous secondary measures.
Keywords: fibromyalgia, duloxetine, placebo, double-blind, trial, pain
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Published Date: 5 February 2015
ÇalÄ±k AN, Özcan KS, Yüksel G, Güngör B, AruÄŸarslan E, Varlibas F, Ekmekci A, Osmonov D, TatlÄ±su MA, Karaca M, Bolca O, Erdinler I
Published Date: 16 July 2014
Carvalho A, Rea IM, Parimon T, Cusack BJ
Published Date: 12 April 2014
The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy
Sterjev Z, Trencevska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, Nestorovska AK, Matevska N, Naumovska Z, Jolevska-Trajkovic S, Dimovski A, Suturkova L
Published Date: 19 April 2012
Nordfjeld K, Andreasen H, Thomsen LL
Published Date: 5 March 2012
Krikeli M, Ekonomopoulou MT, Tzitzikas I, Goutzioulis A, Mystakidou K, Pistevou-Gompaki K
Published Date: 5 December 2011
Ann G Neff, Matthew Turner, Diya F Mutasim
Published Date: 6 June 2008
Published Date: 15 January 2008
Sidney H Kennedy, Beata S Eisfeld
Published Date: 15 September 2007
A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents
Published Date: 15 July 2007